Overcoming Resistance to CDK4/6 Inhibitors
The standard treatment for ER-positive, HER2-negative MBC is a combination of hormone therapy plus a CDK4/6 inhibitor: palbociclib (Ibrance®), ribociclib...
Read More PAST ARTICLES
2023
- Researching Ways to Make MBC Treatment Easier to Tolerate
- Artificial Intelligence and MBC: Can AI Improve Detection and Treatment?
- The Latest Research on Lobular MBC
- What is the Microbiome and How Might it Affect MBC?
- New ESR1 Biomarker Research Leads to FDA Approval for ER+, HER2- MBC with an ESR1 Mutation
2022
- The Latest Research on CDK 4/6 Inhibitors
- Why You Should Consider Repeat Biopsies
- All About Vaccines for MBC
- Triple-Negative Metastatic Breast Cancer: Beyond ER, PR, and HER2
- Update on Immunotherapy for MBC: Immune Checkpoint Inhibitors
- Update On Antibody-Drug Conjugates (ADCs) For MBC
- Bispecific Antibodies: An Emerging Class Of MBC Drugs
2021
- What do FGFR Genetic Mutations Mean for You and Your MBC?
- Metronomic Chemotherapy: Looking at A New Way to Receive Treatment
- Inflammatory MBC Treatments
- Theragnostics
- Atezolizumab Immunotherapy Is Withdrawn From FDA-Approval Process
- Cell-Based Therapies: A Type of Immunotherapy for MBC
- Update on Oral SERDs for Estrogen Receptor-Positive MBC
- Y-90 Internal Radiation Therapy for Liver Mets
- The Latest Research on Hormone Receptor-Positive (HR+) MBC
- 2021 Update on Metastatic Triple Negative Breast Cancer Treatment
- Treating Breast Cancer Brain Mets
- Lines of Therapy: New Drugs May Change MBC Treatment
2020
- When to Use Surgery & Radiation to the Breast
- HER2-Low Expressing: A New Subcategory of HER2-Negative Breast Cancer?
- PD-L1 Biomarker for Immunotherapy
- What is ER-Low Breast Cancer?
- HER2 Positive Metastatic Breast Cancer Research Update
- Recent FDA Approvals for Metastatic Breast Cancer
- The Tumor Microenvironment
- What is Your Tumor’s Mutation Burden?
- Triple-Negative Breast Cancer Update
2019
- Tips for Reading Cancer News
- What is a Tumor Agnostic Therapy?
- Treating Brain Metastases
- New FDA Approval: A PI3K Inhibitor
- What is Oligometastatic Breast Cancer?
- First Immunotherapy Approved for MBC
- The Latest Research on ctDNA and MBC
- Get the Latest News on PARP Inhibitors
- New Research Presented at San Antonio
SEARCH OUR SITE
for past articles or specific information.